Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Califf

Showing results (211-220 of 770) with videos related to

Pageof 77
Sort By:
JAMA|February 27, 2009
Scientific evidence underlying the ACC/AHA clinical practice guidelinesPierluigi Tricoci, Joseph M Allen, Judith M Kramer, et al.
American Journal of Hypertension|February 19, 2013
Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trialRanee Chatterjee, Laine Thomas, Laura Svetkey, et al.
NPJ Digital Medicine|December 25, 2019
Digital clinical trials: creating a vision for the futureSteven R Steinhubl, Dana L Wolff-Hughes, Wendy Nilsen, et al.
JAMA|April 24, 2003
What clinicians should know about the QT intervalSana M Al-Khatib, Nancy M Allen LaPointe, Judith M Kramer, et al.
JACC. Heart Failure|March 4, 2017
JACC: Heart Failure Series: FDA in the 21st Century: Focus on Nutrition and Heart Failure PreventionMona Fiuzat, Susan T Mayne, Matt Hillebrenner, et al.
Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc|July 10, 2003
Knowledge deficits related to the QT interval could affect patient safetyNancy M Allen LaPointe, Sana M Al-Khatib, Judith M Kramer, et al.
The New England Journal of Medicine|March 4, 2011
The ClinicalTrials.gov results database--update and key issuesDeborah A Zarin, Tony Tse, Rebecca J Williams, et al.
American Heart Journal|July 3, 2002
Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary ArteriesIan C Gilchrist, Scott D Berkowitz, Trevor D Thompson, et al.
Hypertension (Dallas, Tex. : 1979)|February 21, 2008
Safety of placebo controls in pediatric hypertension trialsP Brian Smith, Jennifer S Li, M Dianne Murphy, et al.
The Journal of Clinical Investigation|December 3, 2020
Generating evidence for therapeutic effects: the need for well-conducted randomized trialsRobert M Califf, Lesley H Curtis, Robert A Harrington, et al.
Pageof 77

Showing results (211-220 of 770) with videos related to

Sort By:
Pageof 77
JAMA|February 27, 2009
Scientific evidence underlying the ACC/AHA clinical practice guidelinesPierluigi Tricoci, Joseph M Allen, Judith M Kramer, et al.
American Journal of Hypertension|February 19, 2013
Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trialRanee Chatterjee, Laine Thomas, Laura Svetkey, et al.
NPJ Digital Medicine|December 25, 2019
Digital clinical trials: creating a vision for the futureSteven R Steinhubl, Dana L Wolff-Hughes, Wendy Nilsen, et al.
JAMA|April 24, 2003
What clinicians should know about the QT intervalSana M Al-Khatib, Nancy M Allen LaPointe, Judith M Kramer, et al.
JACC. Heart Failure|March 4, 2017
JACC: Heart Failure Series: FDA in the 21st Century: Focus on Nutrition and Heart Failure PreventionMona Fiuzat, Susan T Mayne, Matt Hillebrenner, et al.
Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc|July 10, 2003
Knowledge deficits related to the QT interval could affect patient safetyNancy M Allen LaPointe, Sana M Al-Khatib, Judith M Kramer, et al.
The New England Journal of Medicine|March 4, 2011
The ClinicalTrials.gov results database--update and key issuesDeborah A Zarin, Tony Tse, Rebecca J Williams, et al.
American Heart Journal|July 3, 2002
Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary ArteriesIan C Gilchrist, Scott D Berkowitz, Trevor D Thompson, et al.
Hypertension (Dallas, Tex. : 1979)|February 21, 2008
Safety of placebo controls in pediatric hypertension trialsP Brian Smith, Jennifer S Li, M Dianne Murphy, et al.
The Journal of Clinical Investigation|December 3, 2020
Generating evidence for therapeutic effects: the need for well-conducted randomized trialsRobert M Califf, Lesley H Curtis, Robert A Harrington, et al.
Pageof 77